| Primary |
| Tuberculosis |
72.1% |
| Disseminated Tuberculosis |
9.3% |
| Cutaneous Tuberculosis |
4.7% |
| Lymph Node Tuberculosis |
4.7% |
| Mycobacterium Avium Complex Infection |
4.7% |
| Meningitis Tuberculous |
2.3% |
| Mycobacterial Infection |
2.3% |
|
| Drug Ineffective |
23.5% |
| Hepatitis |
17.6% |
| Blindness |
5.9% |
| Macular Degeneration |
5.9% |
| Ocular Toxicity |
5.9% |
| Optic Neuritis |
5.9% |
| Pain |
5.9% |
| Syncope |
5.9% |
| Visual Acuity Reduced |
5.9% |
| Visual Disturbance |
5.9% |
| Visual Impairment |
5.9% |
| Vomiting |
5.9% |
|
| Secondary |
| Tuberculosis |
21.6% |
| Hiv Infection |
17.6% |
| Drug Use For Unknown Indication |
15.0% |
| Product Used For Unknown Indication |
8.1% |
| Disseminated Tuberculosis |
7.2% |
| Pulmonary Tuberculosis |
5.6% |
| Mycobacterium Avium Complex Infection |
3.7% |
| Prophylaxis |
3.7% |
| Mycobacterial Infection |
3.1% |
| Atypical Mycobacterial Infection |
2.2% |
| Meningitis Tuberculous |
1.7% |
| Meningitis Aseptic |
1.5% |
| Anaemia |
1.4% |
| Insomnia |
1.4% |
| Maternal Exposure During Pregnancy |
1.3% |
| Ankylosing Spondylitis |
1.0% |
| Infective Tenosynovitis |
1.0% |
| Toxoplasmosis |
1.0% |
| Antifungal Prophylaxis |
0.9% |
| Ill-defined Disorder |
0.9% |
|
| Vomiting |
14.1% |
| Pyrexia |
8.5% |
| Rash Maculo-papular |
7.0% |
| Lymphadenopathy |
6.3% |
| Tuberculosis |
6.3% |
| Immune Reconstitution Syndrome |
5.6% |
| Sputum Discoloured |
5.6% |
| Toxic Skin Eruption |
5.6% |
| Hepatitis Fulminant |
4.9% |
| Agranulocytosis |
4.2% |
| Rash |
4.2% |
| Renal Failure Acute |
4.2% |
| Impaired Gastric Emptying |
3.5% |
| Transaminases Increased |
3.5% |
| Cholestasis |
2.8% |
| Hepatic Enzyme Increased |
2.8% |
| Neutropenia |
2.8% |
| Optic Neuritis |
2.8% |
| Tuberculosis Liver |
2.8% |
| Cardiac Failure |
2.1% |
|
| Concomitant |
| Hiv Infection |
23.9% |
| Tuberculosis |
20.1% |
| Product Used For Unknown Indication |
10.0% |
| Mycobacterium Avium Complex Infection |
7.9% |
| Pulmonary Tuberculosis |
7.4% |
| Drug Use For Unknown Indication |
6.6% |
| Prophylaxis |
5.7% |
| Antifungal Prophylaxis |
3.0% |
| Atypical Mycobacterial Infection |
2.6% |
| Mycobacterial Infection |
2.0% |
| Hypertension |
1.5% |
| Disseminated Tuberculosis |
1.2% |
| Anaemia |
1.1% |
| Breast Cancer |
1.1% |
| Fungal Infection |
1.1% |
| Crohn's Disease |
1.1% |
| Liver Transplant |
1.1% |
| Acquired Immunodeficiency Syndrome |
0.9% |
| Pain |
0.9% |
| Antiretroviral Therapy |
0.8% |
|
| Pyrexia |
13.5% |
| Subdural Haematoma |
11.1% |
| Vomiting |
9.5% |
| Renal Failure Acute |
7.9% |
| Tuberculosis |
7.1% |
| Renal Failure |
6.3% |
| Hepatic Failure |
4.8% |
| Lymphadenopathy |
4.8% |
| Mixed Liver Injury |
4.0% |
| Pulmonary Tuberculosis |
4.0% |
| Hepatocellular Injury |
3.2% |
| Neutropenia |
3.2% |
| Rash Maculo-papular |
3.2% |
| Urticaria |
3.2% |
| Electroencephalogram Abnormal |
2.4% |
| Gamma-glutamyltransferase Increased |
2.4% |
| Hepatic Artery Thrombosis |
2.4% |
| Immune Reconstitution Syndrome |
2.4% |
| Impaired Gastric Emptying |
2.4% |
| Lymphadenitis |
2.4% |
|
| Interacting |
| Disseminated Tuberculosis |
46.2% |
| Combined Immunodeficiency |
30.8% |
| Pain |
15.4% |
| Essential Hypertension |
7.7% |
|
|
